ALGS
Income statement / Annual
Last year (2025), Aligos Therapeutics Inc's total revenue was $2.19 M,
a decrease of 44.59% from the previous year.
In 2025, Aligos Therapeutics Inc's net income was -$24.19 M.
See Aligos Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$2.19 M |
$3.95 M |
$15.53 M |
$13.91 M |
$4.36 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$930.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.33 M
|
$2.30 M
|
$1.29 M
|
| Gross Profit |
$1.26 M
|
$3.95 M
|
$15.53 M
|
$13.91 M
|
$4.36 M
|
-$3.33 M
|
-$2.30 M
|
-$1.29 M
|
| Gross Profit Ratio |
0.57
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$69.45 M
|
$70.27 M
|
$73.04 M
|
$85.08 M
|
$104.15 M
|
$79.89 M
|
$44.04 M
|
$10.46 M
|
| General & Administrative Expenses |
$20.72 M
|
$22.83 M
|
$30.62 M
|
$26.41 M
|
$28.53 M
|
$0.00
|
$10.01 M
|
$3.21 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.72 M
|
$22.83 M
|
$30.62 M
|
$26.41 M
|
$28.53 M
|
$14.62 M
|
$10.01 M
|
$3.21 M
|
| Other Expenses |
-$930.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$302.00 K
|
-$435.00 K
|
| Operating Expenses |
$89.24 M
|
$93.10 M
|
$103.66 M
|
$111.49 M
|
$132.68 M
|
$94.51 M
|
$54.04 M
|
$13.66 M
|
| Cost And Expenses |
$90.17 M
|
$93.10 M
|
$103.66 M
|
$111.49 M
|
$132.68 M
|
$97.83 M
|
$54.04 M
|
$13.66 M
|
| Interest Income |
$2.16 M
|
$1.67 M
|
$1.24 M
|
$1.64 M
|
$132.00 K
|
$1.26 M
|
$1.86 M
|
$163.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10.55 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$930.00 K
|
$2.62 M
|
$3.07 M
|
$3.68 M
|
$3.78 M
|
$3.33 M
|
$2.30 M
|
$1.29 M
|
| EBITDA |
-$87.06 M |
-$86.53 M |
-$85.06 M |
-$93.91 M |
-$124.54 M |
-$105.06 M |
-$49.88 M |
-$12.37 M |
| EBITDA Ratio |
-39.82
|
-21.93
|
-5.48
|
-6.75
|
-28.57
|
0
|
0
|
0
|
| Operating Income Ratio |
-40.25
|
-22.6
|
-5.67
|
-7.02
|
-29.44
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$64.11 M
|
-$41.73 M
|
$1.24 M
|
$1.64 M
|
$132.00 K
|
-$10.55 M
|
$1.86 M
|
-$272.00 K
|
| Income Before Tax |
-$23.88 M
|
-$130.88 M
|
-$86.88 M
|
-$95.94 M
|
-$128.19 M
|
-$108.38 M
|
-$52.18 M
|
-$13.93 M
|
| Income Before Tax Ratio |
-10.92
|
-33.18
|
-5.59
|
-6.9
|
-29.41
|
0
|
0
|
0
|
| Income Tax Expense |
$314.00 K
|
$331.00 K
|
$795.00 K
|
$106.00 K
|
$143.00 K
|
$161.00 K
|
$85.00 K
|
$0.00
|
| Net Income |
-$24.19 M
|
-$131.21 M
|
-$87.68 M
|
-$96.05 M
|
-$128.33 M
|
-$108.54 M
|
-$52.26 M
|
-$13.93 M
|
| Net Income Ratio |
-11.07
|
-33.26
|
-5.65
|
-6.91
|
-29.44
|
0
|
0
|
0
|
| EPS |
-2.45 |
-20.94 |
-3.52 |
-2.25 |
-3.22 |
-3.18 |
-2.38 |
-0.66 |
| EPS Diluted |
-2.45 |
-20.94 |
-3.52 |
-2.25 |
-3.22 |
-3.18 |
-2.38 |
-0.66 |
| Weighted Average Shares Out |
$9.88 M
|
$6.26 M
|
$24.87 M
|
$42.70 M
|
$39.86 M
|
$34.18 M
|
$21.93 M
|
$21.17 M
|
| Weighted Average Shares Out Diluted |
$9.88 M
|
$6.26 M
|
$24.87 M
|
$42.70 M
|
$39.86 M
|
$34.18 M
|
$21.93 M
|
$21.17 M
|
| Link |
|
|
|
|
|
|
|
|
